ArticleCommunications biology2025
Revealing acute consequences of rapid degradation of synaptic fusion proteins at individual synapses using Auxin-Inducible Degron 2 technology.
Article in Communications biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Roles of particular proteins in synaptic organization and function are commonly studied by knock-out, knock-down or overexpression strategies. Such approaches are typically protracted, associated with adaptive changes and challenge the ability to observe acute consequences at individual synapses. Here we describe the use of Auxin-Inducible Degron 2 (AID2) technology and coexpressed reporters to study real-time effects of rapidly degrading postsynaptic density proteins at individual synapses. We establish the capacity of AID2 technology to rapidly degrade postsynaptic scaffold fusion proteins in cultured neurons and in vivo. We show that acute PSD-95 or gephyrin degradation leads to concomitant loss of AMPA or GABA
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.